Når decarboxyleringen af levodopa reduceres ved samtidig administration af en DDC- hæmmer, kan en lavere dosis af levodopa benyttes, og forekomsten af uønskede virkninger så som kvalme reduceres.
When decarboxylation of levodopa is reduced with the co-administration of a DDC inhibitor, a lower dose of levodopa can be used and the incidence of undesirable effects such as nausea is reduced.